Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trialResearch in context

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trialResearch in context

Summary: Background: COVID-19 vaccines that offer broad-spectrum protection are needed. We aimed to evaluate the safety and immunogenicity of multivalent vaccines, SCTV01E and SCTV01C, and compare them with an inactivated vaccine. Methods: In the phase 3 trial (ClinicalTrials.gov: NCT05323461), adu...

Full description

Bibliographic Details
Main Authors: Suad Hannawi, Lixin Yan, Linda Saifeldin, Alaa Abuquta, Ahmad Alamadi, Sally A. Mahmoud, Aala Hassan, Miaomiao Zhang, Cuige Gao, Yuanxin Chen, Wenlin Gai, Liangzhi Xie
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:EClinicalMedicine
Subjects:
Safety
Immunogenicity
SARS-CoV-2
Tetravalent vaccine
Booster
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023003723

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023003723

Similar Items